"bavituximab and Cotara are still in a relatively early stage of development"
"As we continue to generate positive patient data"
"additional clinical data is essential if we are to do so. To generate that data requires capital"
"the company is prepared to implement a reverse split"
Reality check people. Anyone happy with that reply isn't paying attention. Remember it's their job to put as positive a spin on as posible, and I didn't even see anything positive reading betwen the lines.
My translation of the above:
NOTHING has changed as always. There's a long way to go before they make a significant deal or create value for shareholders. In the mean time, they need
more data , more trials, more time, more money, more dilution, and a reverse split.
Wow, what a disaster.
Oh, by the way, they want some new stock option awards!
PROPOSAL #4 is the only hope I see for shareholder value creation, but I doubt it passes, sorry guys.